Civil procedure; Oklahoma Evidence Code; medical bills; admissible evidence; effective date.
HB2612 amends Oklahoma civil procedure law governing what medical expense evidence may be presented in personal injury cases. For past medical treatment, the bill generally limits admissible evidence to the actual amounts paid rather than the amounts originally billed. It also allows billed amounts above what was paid to be admitted only in limited circumstances, such as when a medical provider has filed a lien for an amount greater than the payment received.
The bill creates a separate rule for cases where no payment has been made. In those situations, the admissible amount is tied to Medicare reimbursement rates, but only if the provider agrees in writing or by sworn testimony to accept that amount as full payment. If no such statement is provided by the final pretrial hearing, the billed amount may be used to establish reasonable value, subject to lien-related limits and restrictions tied to what could be satisfied through insurance or public health coverage. The bill also adds a new section for future medical treatment, generally limiting evidence to amounts actually necessary to satisfy the obligation and, when reimbursement cannot otherwise be determined, making Medicare rates the admissible benchmark.
HB2612 would amend 12 O.S. 2021, Section 3009.1, and add a new Section 3009.2 to Title 12. Its practical effect would be to narrow the evidence juries may hear about medical damages in personal injury litigation, shifting the focus from gross billed charges to paid amounts, Medicare-based rates, or amounts actually necessary to satisfy future treatment obligations. The bill applies prospectively to personal injury actions filed on or after November 1, 2025 for the new future-treatment section, while the amended past-treatment section states application to actions filed on or after November 1, 2015.
The available context shows little recorded debate: there are no committee transcripts and no votes listed, and the bill was referred to the House Civil Judiciary Committee. Based on the text, the measure appears aimed at reducing inflated medical-damages evidence and standardizing valuation of medical expenses in tort cases. The overall sentiment inferred from the bill language is policy-driven and reform-oriented, with an emphasis on limiting recoverable or admissible medical billing evidence rather than expanding it.
The main point of contention likely concerns how the bill would affect plaintiffs, insurers, and healthcare providers in personal injury cases. Supporters would likely view it as a way to curb excessive or speculative medical billing evidence and align damages with actual payment obligations. Critics may argue that tying admissibility to paid amounts, Medicare rates, or insurance reimbursement could undervalue medical care, disadvantage uninsured or underinsured plaintiffs, and reduce jury consideration of the full market value of treatment.
The bill would amend Oklahoma’s evidence rules for personal injury civil actions by changing what medical expense amounts are admissible at trial. It would revise 12 O.S. 2021, Section 3009.1, and create new Section 3009.2 in Title 12, affecting how past and future medical damages are proven. The measure would primarily affect injured plaintiffs, defendants, insurers, medical providers, and courts handling tort cases by limiting evidence to paid amounts, Medicare reimbursement rates, or amounts necessary to satisfy financial obligations, rather than billed charges.
There is no recorded committee testimony or vote history in the provided context, so the public legislative sentiment cannot be measured directly. The bill’s text suggests a reform-minded approach focused on limiting medical-billing evidence in personal injury litigation, which typically appeals to tort-reform supporters. At the same time, the absence of recorded debate leaves open the possibility of opposition from plaintiff-side advocates, uninsured claimants, and healthcare providers concerned about reduced damage valuations.
The likely controversy centers on whether personal injury plaintiffs should be limited to evidence of actual payments or Medicare-based reimbursement rather than full billed charges. Supporters would likely argue the bill prevents inflated medical bills from distorting damages awards and better reflects real economic loss. Opponents may contend that Medicare rates are not an appropriate proxy for all patients, that the bill could undervalue future care, and that it may unfairly burden uninsured or underinsured injured parties whose providers may bill more than public-program rates. The treatment of medical liens and the requirement for provider statements or sworn testimony may also be disputed.